Why did 4598.T stock fall pre-market today?

4598.T stock fell **-18.15%** pre-market to **JPY 451.00** amid elevated concern over Phase III outcomes and a prior C- analyst rating. Low pre-market volume amplified the move. Confirm any catalyst with company releases before trading.

What is Meyka AI’s view on 4598.T stock valuation?

Meyka AI rates 4598.T at **67.34/100 (B, HOLD)**, noting negative EPS and high PB of **14.48**. The model values clinical potential but flags execution risk and binary trial outcomes as valuation drivers.

What downside risk should investors expect for 4598.T stock?

Downside risks include failed Phase III readouts, slower enrollment and funding needs. Technical oversold signals can mask further falls; a bear scenario could push price toward the **JPY 400.00** region if catalysts are negative.

What forecast does Meyka AI give for 4598.T stock?

Meyka AI’s forecast model projects a yearly target of **JPY 478.97**, implying a **6.20%** upside from **JPY 451.00**. Forecasts are model-based projections and not guarantees.

JP Stocks

PRE MARKET: 4598.T Delta-Fly Pharma down 18.15% to JPY 451.00: clinical readouts in focus

ByDanny Kontos January 13, 2026January 13, 2026

4598.T stock opened the pre-market session sharply lower, trading at JPY 451.00 after a -18.15% drop from the previous close of JPY 551.00. Volume is subdued at 26,900.00 shares versus an average of 617,989.00, indicating panic selling by short-term holders rather than broad repositioning. The move follows renewed trader focus on upcoming Phase III readouts and a negative company rating dated 2026-01-09. We examine price action, fundamentals, clinical catalysts and what the drop means for investors in Japan’s JPX-listed Delta-Fly Pharma, Inc.